Tappan Street Partners’s Biostage, Inc. Common Stock BSTG Stock Holding History

Tappan Street Partners’s Portfolio BSTG Stock Details BSTG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-265,018	Closed	-$284K	–	18
2016 Q3	$284K	Sell	265,018 -34,982	-12%	-$37.7K	0.38%	14
2016 Q2	$342K	Hold	300,000	–	–	0.42%	19
2016 Q1	$540K	Hold	300,000	–	–	0.66%	16
2015 Q4	$654K	Buy	+300,000	New	+$418K	0.85%	14

Other funds holding BSTG

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

WIC

Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tappan Street Partners's BSTG Position: Q4 2016 in Review

Tappan Street Partners sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2016, closing a stake of 265,018 shares — an estimated $284K sold.

Tappan Street Partners first reported a position in BSTG in Q4 2015 and held it in 4 quarters. The position peaked at $654K in Q4 2015. 27 funds tracked by Wall St. Rank hold BSTG as of Q4 2016.

Tappan Street Partners reported no remaining Biostage, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Tappan Street Partners sold 265,018 Biostage, Inc. Common Stock shares in Q4 2016, an estimated $284K.
Tappan Street Partners first reported a position in Biostage, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
Tappan Street Partners's Biostage, Inc. Common Stock position peaked at $654K in Q4 2015.
27 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2016.

Based on Tappan Street Partners's 13F filing for Q4 2016, filed 14 Feb 2017.